Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.

Conclusion: Overall resource use and costs for BTH are estimated to be lower for PNH patients receiving ravulizumab compared with eculizumab.
PMID: 32856539 [PubMed - in process]

Source: Hematology - August 29, 2020 Category: Hematology Tags: Hematology Source Type: research